BofA raised the firm’s price target on Intra-Cellular to $92 from $91 and keeps a Buy rating on the shares after the company reported positive Phase 3 data from its second confirmatory adjunctive MDD trial. Based on the Study 502 outcome, the firm removed risk-adjustments on the MDD program and now sees 100% probability of success and an approval in the second half of 2025, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
- Intra-Cellular price target raised to $78 from $75 at JPMorgan
- Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
- Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference
- Intra-Cellular participates in a conference call with JPMorgan